Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
November 08, 2018 16:44 ET
|
Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy
September 06, 2018 07:11 ET
|
Intrommune Therapeutics
New York, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
May 15, 2018 12:00 ET
|
Intrommune Therapeutics
New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Therapeutics Announces Crowdfunding Financing Campaign to Support Food Allergy Treatment Research
May 09, 2018 10:36 ET
|
Intrommune Therapeutics
New York, May 09, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of...
Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference
April 24, 2018 09:27 ET
|
Intrommune Therapeutics
New York, April 24, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced today that it...
Intrommune Therapeutics Announces Expansion of Advisory Board with Three Top Food Allergy Experts
June 14, 2016 07:30 ET
|
Intrommune Therapeutics
New York, June 14, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
Intrommune Therapeutics to Present at 2016 BIO International Convention
June 06, 2016 07:55 ET
|
Intrommune Therapeutics
New York, June 06, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
Intrommune Therapeutics Announces Positive Results of Proof-of-Concept study of Oral Mucosal Immunotherapy (OMIT) Platform for the Treatment of Allergies
April 25, 2016 09:08 ET
|
Intrommune Therapeutics
Patient-friendly platform treats allergies while a patient brushes their teeth Oral mucosal route of administration demonstrated to be efficacious No gastrointestinal side effects...
Intrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 01, 2016 07:10 ET
|
Intrommune Therapeutics
New York, March 01, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced...
Intrommune Therapeutics to Present at New York Venture Capital Association 2016 Health & Bio Technology Summit
February 22, 2016 07:15 ET
|
Intrommune Therapeutics
New York, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...